Today, the world’s first automated simultaneous lecture translation
was demonstrated at the University Without Language Barriers
conference at the Karlsruhe Institute of Technology (KIT) in Germany.
Using this groundbreaking system, non-German speaking students can now
participate in live ... read more
First graph, last sentence of release should read: HCI, a pioneer and
leader in community health improvement technologies, was presented the
award on June 5 by Assistant Secretary for Health for the U.S.
Department of Health and Human Services (HHS), Howard Koh, M.D., M.P.H.
(sted HCI, ... read more
Holocom, the leader in protective distribution systems (PDS) for SIPRNet
and other classified networks, announced the promotion of two managers to
key corporate positions. Scott R. Beeson, former Senior Vice President &
Chief Operating Officer, has been promoted to President & Chief Operating
Officer. Mr. Beeson also was appointed to the Board of Directors.
Beeson is integral to core decisions concerning finance, strategy, and
corporate direction and has been leading Holocom’s day-to-day operations
for almost two years. A mechanical engineer and former US Marine Corps
captain with specialized ... read more
Infoblox Inc. (NYSE:BLOX) today announced the Company will be
participating in Interop Tokyo, June 13 – 15, 2012, demonstrating
Infoblox’s automated network control solutions that take the burden of
complex network control out of human hands, reduce costs, and increase
accuracy and uptime.
... read more
Micronetics, Inc. (NASDAQ: NOIZ) announced today that it has signed a
definitive merger agreement with Mercury Computer Systems, Inc. (NASDAQ:
and a new Mercury subsidiary under which Mercury will acquire
Micronetics for $14.80 per common share in cash. The transaction is
... read more
MIAMI, FL -- (Marketwire) -- 06/10/12 -- In the few short years since PET/CT became a multi-modal procedure of choice for cancer staging and therapy assessment, many providers are now facing tough competition from the growing number of scanning services entering their markets. Mirada Medical has developed their entire product line to offer customers innovative ways to differentiate their PET/CT service and improve workflow efficiency. The company will be demonstrating how successful PET/CT providers are competing more effectively ... read more
Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women. Treatment with beloranib was associated with improvements in weight loss and triglycerides, LDL cholesterol, waist circumference and diastolic blood pressure, with no evidence of major tolerability or safety issues. ... read more
It could be argued that being an Orlando Web Design Company is a bit like being a barber, people always need their hair cut and barber's do not technically shift or sell any stock or inventory. To that end web design is also an intangible but on-going business, just as hair is always growing (supplying a need for barbers and hairdressers); the web is also 'growing' and evolving and web designs need to be updated regularly to keep up with ... read more
The Great Comebacks® Program today presented Harriet Pilert, RN, MS, COCN with the WOC Nurse Great Comebacks® Award at the opening ceremony of the Wound, Ostomy and Continence Nurses (WOCN®) Society(TM) 44th Annual Conference in Charlotte, NC. The Great Comebacks® Program annually honors outstanding individuals, including the specialist WOC nurses who inspire their patients to live life to the fullest after ostomy surgery. Pilert is an ostomy and continence nurse at Mercy Medical Center in Baltimore, MD. The award ... read more
Systems, Inc. today announced its support, along with Cisco
Systems, of the Lowell
Transitional Living Center’s first fundraising walk. NetScout and
Cisco will provide donations for the Center’s Steps
to Home initiative in support of the organization’s ongoing efforts ... read more
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a post-hoc analysis, which explored the clinical effect of linagliptin on albuminuria in patients with type 2 diabetes who had early diabetic nephropathy (renal disease). The primary endpoint of the analysis was changes to the urinary albumin-to-creatinine ratio (UACR), which is a measure of renal function in patients with type 2 diabetes and diabetic nephropathy.
This post-hoc analysis, which is being presented at ... read more
Attached is a press
release issued earlier this morning by GlaxoSmithKline,
announcing that detailed findings from the Harmony 6 Phase 3 study
comparing albiglutide to prandial insulin (Lispro), were presented today
at the American Diabetes Association Meeting (ADA) in Philadelphia, USA,
... read more
PHILADELPHIA, PA -- (Marketwire) -- 06/09/12 -- Diartis Pharmaceuticals, Inc. today presented positive data from its recently completed Phase 1 multicenter clinical trial of VRS-859 (exenatide-XTEN) at the American Diabetes Association's 72nd Scientific Sessions, which began yesterday in Philadelphia. VRS-859, a long-acting glucagon-like peptide-1 (GLP-1) analog, is being developed as a once monthly treatment for patients with type 2 diabetes mellitus (T2DM). The Diartis poster -- "Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Administration of VRS-859 in ... read more
Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta(TM), the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing. The half-life of Ersatta was 6-7 days compared to one hour for the naturally occurring C-peptide. Ersatta is being developed as a disease-modifying treatment initially for diabetic peripheral neuropathy and eventually as a treatment for all microvascular ... read more
RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/-- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results that showed empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1C) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks. A1C is measured in people with diabetes to provide an index of blood glucose control ... read more
Ultra long-acting insulin degludec, an investigational insulin being developed by Novo Nordisk, significantly reduced the rate of hypoglycemia* at night in adults with type 2 diabetes while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period. This phase 3a study was presented today at the 72nd Scientific Sessions of the American Diabetes Association (ADA).
To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/56709-novo-nordisk-degludec-ultra-long-acting-insulin-hypoglycemia-diabetes
(Photo: http://photos.prnewswire.com/prnh/20120609/MM21573LOGO )
The study also found that insulin degludec had significantly ... read more
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions®. The new studies provide additional data evaluating the efficacy and safety of linagliptin (alone or in combination with other diabetes therapies) in adults with type 2 diabetes.,, Linagliptin, marketed in the U.S. as Tradjenta®, is a once-daily tablet that is used along with diet and ... read more
Metabolic Solutions Development Company, LLC (MSDC) presented Phase 2b results for MSDC-0160 today at the 72nd Scientific Sessions of the American Diabetes Association. The data showed this novel once-a-day oral insulin sensitizer, the first in a new class of therapeutic agents called mTOT Modulators(TM), met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and significantly reduced hemoglobin A1c (HbA1c).
Of particular importance, the data showed that changes in body weight, hemoglobin, ... read more
Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in monotherapy and in add-on combination use showing that canagliflozin provided substantial and sustained glycemic improvements in adult patients with type 2 diabetes, and was generally well tolerated. In two of these studies comparing canagliflozin to current standard treatments, sitagliptin and glimepiride, canagliflozin dosed once-daily at 300 mg provided significantly greater reductions in A1C levels relative to both comparators with similar overall incidence of ... read more
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets.
Presenters will be available to discuss the posters at the following times:
-- "Human Hyaluronidase Plus Rapid Analog Insulin (RAI) Improves
Postprandial Glycemic Control in Type ... read more